Analyst Activity – William Blair Initiates Coverage On Audentes Therapeutics (NASDAQ:BOLD) With a Outperform

Analyst Ratings For Audentes Therapeutics (NASDAQ:BOLD)

Story continues below

Today, William Blair initiated coverage on Audentes Therapeutics (NASDAQ:BOLD) with a Outperform with a price target of $35.00.

There are 1 hold rating, 5 buy ratings on the stock.

The current consensus rating on Audentes Therapeutics (NASDAQ:BOLD) is Buy (Score: 2.83) with a consensus target price of $26.17 per share, a potential 4.71% upside.

Some recent analyst ratings include

  • 10/17/2017-William Blair initiated coverage with a Outperform rating.
  • 10/12/2017-Raymond James Financial, Inc. initiated coverage with a Mkt Perform rating.
  • 9/22/2017-Bank of America Corporation Reiterated Rating of Buy.
  • 8/16/2017-Evercore ISI initiated coverage with a Outperform rating.
  • 5/15/2017-Wedbush Reiterated Rating of Ourperform.
  • 5/1/2017-Leerink Swann initiated coverage with a Outperform rating.

Recent Insider Trading Activity For Audentes Therapeutics (NASDAQ:BOLD)
Audentes Therapeutics (NASDAQ:BOLD) has insider ownership of 47.30% and institutional ownership of 77.09%.

  • On 10/2/2017 Matthew R Patterson, CEO, sold 25,000 with an average share price of $27.92 per share and the total transaction amounting to $698,000.00. View SEC Filing
  • On 9/29/2017 Louis G Lange, Director, sold 11,000 with an average share price of $28.35 per share and the total transaction amounting to $311,850.00. View SEC Filing
  • On 9/29/2017 Orbimed Advisors Llc, Major Shareholder, sold 672,000 with an average share price of $28.25 per share and the total transaction amounting to $18,984,000.00. View SEC Filing
  • On 9/27/2017 David Nagler, SVP, sold 3,750 with an average share price of $30.00 per share and the total transaction amounting to $112,500.00. View SEC Filing
  • On 9/25/2017 Louis G Lange, Director, sold 18,000 with an average share price of $28.32 per share and the total transaction amounting to $509,760.00. View SEC Filing
  • On 9/18/2017 Matthew R Patterson, CEO, sold 10,000 with an average share price of $25.06 per share and the total transaction amounting to $250,600.00. View SEC Filing
  • On 9/15/2017 David Nagler, SVP, sold 3,750 with an average share price of $25.00 per share and the total transaction amounting to $93,750.00. View SEC Filing

Recent Trading Activity for Audentes Therapeutics (NASDAQ:BOLD)
Shares of Audentes Therapeutics closed the previous trading session at with shares trading hands.

An ad to help with our costs